2023 · European journal of drug metabolism and pharmacokinetics · paywalled
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study
de Klaver et al.
The finding, in our words
Early at-home VAMS samples allowed Bayesian forecasting of steady-state adalimumab concentrations with modest bias (mean prediction error -2.6%) and acceptable precision (normalised RMSE 24.0%), correctly classifying 75% of predictions within the therapeutic window and identifying 8.3% of patients who developed anti-adalimumab antibodies, supporting decentralised precision dosing during induction.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Huhn & Scherf-Clavel, Therapeutic drug monitoring (paywalled) · source ↗
A phase 1 trial designed around participant self-collection of pharmacokinetic samples at home, with video training and pre-assembled kits: evidence that the model is a training and logistics package, not only a device.
Raoufinia et al., Clinical Pharmacology in Drug Development · source ↗
This study established conversion methods for estimating plasma concentrations from whole blood VAMS samples for seven out of ten oral anticancer drugs, finding good agreement between capillary and venous samples. Patients reported a positive experience with home sampling using this microsampling technique.
Meertens et al., Therapeutic drug monitoring · source ↗